Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOxTROT 2: Neo-adjuvant Chemotherapy in Elderly Colon Cancer Patients
NCT06293625Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jun 2024
- Primary completion
- Jun 2032
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of folinic acid, fluorouracil and oxaliplatin in colon cancer (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Disease-Free Survival at 3 years. Started Jun 2024; status: recruiting.
02
Drugs
folinic acidfluorouraciloxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06293625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293625.